TransMedics(US:TMDX)2025-10-29 20:11Financial Performance - Total revenue for Q3 2025 was $143.8 million, a 32% increase from $108.8 million in Q3 2024[4] - Gross margin improved to 59% in Q3 2025, up from 56% in Q3 2024[5] - Net income for Q3 2025 was $24.3 million, or 17% of revenue, compared to $4.2 million in Q3 2024[6] - The company raised its full year 2025 revenue guidance to a range of $595 million to $605 million, representing a 36% growth at the midpoint compared to the previous year[7] - Operating expenses for Q3 2025 were $61.3 million, an increase from $56.9 million in Q3 2024, driven by higher research and development investments[5] - Research and development expenses in Q3 2025 were $15.3 million, compared to $14.3 million in Q3 2024[14] Assets and Collaborations - Cash reserves were $466.2 million as of September 30, 2025, up from $336.7 million at the end of 2024[16] - The company owned 21 aircraft as of September 30, 2025, and increased to 22 aircraft by October 29, 2025[5] - TransMedics announced a strategic collaboration with Mercedes-Benz Group AG to deploy a fleet of vehicles dedicated to organ transportation in Italy[5] Future Goals - The company aims to perform 10,000 U.S. NOP transplants by 2028, leveraging its OCSTM technology and NOPTM networks[3]